Evidence map›Paper›PMID 25811490›Full record

ArticlePloS one2015

Lipoprotein lipase SNPs rs13702 and rs301 correlate with clinical outcome in chronic lymphocytic leukemia patients.

Ans Rombout, Basile Stamatopoulos, Laurence Lagneaux, Sofie Lust, Fritz Offner, Evelien Naessens, Hanne Vanderstraeten, Bruno Verhasselt, Jan Philippé

Erratum issuedOpen access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.7field-weighted citation impact, top 29% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Ans RomboutDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent University, Ghent, Belgium.
Basile StamatopoulosLaboratory of Clinical Therapy, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Laurence LagneauxLaboratory of Clinical Therapy, Institut Jules Bordet, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Sofie LustDepartment of Hematology, Ghent University Hospital, Ghent University, Ghent, Belgium.
Fritz OffnerDepartment of Hematology, Ghent University Hospital, Ghent University, Ghent, Belgium.
Evelien NaessensDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent University, Ghent, Belgium.
Hanne VanderstraetenDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent University, Ghent, Belgium.
Bruno VerhasseltDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent University, Ghent, Belgium.
Jan PhilippéDepartment of Clinical Chemistry, Microbiology and Immunology, Ghent University Hospital, Ghent University, Ghent, Belgium.
Ghent University Hospital · BEInstitut Jules Bordet · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic lymphocytic leukemia (CLL) is the most common leukemia in the Western world and is characterized by a heterogeneous clinical course. This variability in clinical course has spiked the search for prognostic markers able to predict patient evolution at the moment of diagnosis. Markers demonstrated to be of value are the mutation status of the immunoglobulin heavy chain variable region genes (IGHV) and lipoprotein lipase (LPL) expression. High LPL mRNA expression has been associated with short treatment free (TFS) and decreased overall survival (OS) in CLL. The LPL SNPs rs301 (T<C), rs328 (C<G) and rs13702 (T<C) have been associated with various metabolic disorders, but the association with CLL evolution is unknown. Here, in a cohort of 248 patients, we show that patients with the LPL SNP rs13702 wild-type T/T genotype had significantly shorter OS than patients with C/C and T/C genotypes (median time until CLL related death: 90 and 156 months respectively, p=0.008). The same was observed for LPL SNP rs301 (median time until CLL related death T/T: 102 and C/C, T/C: 144 months, p=0.03). Both SNPs rs301 and rs13702 were significantly associated with each other and notably, no association was found between IGHV status and presence of the SNP genotypes, indicating that these LPL SNPs are reliable prognostic markers that could add extra prognostic and predictive information to classical markers and help to improve the management of CLL.

Indexed as

AdultAgedAged, 80 and overBiomarkers, TumorCohort StudiesHumansImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionKaplan-Meier EstimateLeukemia, Lymphocytic, Chronic, B-CellLipoprotein LipaseMiddle AgedMutationPolymorphism, Single NucleotidePrognosisRNA, MessengerBiomarkers, TumorImmunoglobulin Heavy ChainsImmunoglobulin Variable RegionLipoprotein LipaseRNA, Messenger

Identifiers

PMID25811490
PMCPMC4374908
OpenAlexW2036926994

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.